CADTH Health Technology Review

Autologous Hematopoietic Cell Transplant for Patients With Multiple Sclerosis
Authors: Khai Tran, Hannah Loshak

ISSN: 2563-6596

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to Requests@CADTH.ca
# Table of Contents

List of Tables ................................................................................................................. 4  
List of Figures ................................................................................................................. 5  
Abbreviations ................................................................................................................ 6  
Key Messages ................................................................................................................ 7  
Context and Policy Issues ............................................................................................ 7  
Research Questions ....................................................................................................... 8  
Methods ......................................................................................................................... 8  
  Literature Search Methods ......................................................................................... 8  
  Selection Criteria and Methods .................................................................................. 9  
  Exclusion Criteria ....................................................................................................... 9  
  Critical Appraisal of Individual Studies ..................................................................... 9  
Summary of Evidence .................................................................................................... 9  
  Quantity of Research Available ................................................................................ 9  
  Summary of Study Characteristics .......................................................................... 10  
  Summary of Critical Appraisal .................................................................................. 11  
  Summary of Findings ............................................................................................... 12  
  Limitations ................................................................................................................ 15  
Conclusions and Implications for Decision- or Policy-Making .................................... 16  
References ................................................................................................................... 18  
Appendix 1: Selection of Included Studies .................................................................. 19  
Appendix 2: Characteristics of Included Publications ............................................... 20  
Appendix 3: Critical Appraisal of Included Publications ............................................. 27  
Appendix 4: Main Study Findings and Authors’ Conclusions ..................................... 33  
Appendix 5: References of Potential Interest ............................................................... 44
List of Tables

Table 1: Selection Criteria .......................................................................................................................... 9
Table 2: Characteristics of Included Primary Clinical Studies ..................................................................... 20
Table 3: Characteristics of Included Guidelines ........................................................................................... 25
Table 4: Strengths and Limitations of Clinical Studies Using the Downs and Black Checklist\textsuperscript{13} .......................................................... 27
Table 5: Strengths and Limitations of Guidelines Using AGREE II\textsuperscript{14} ................................................................................................................... 31
Table 6: Summary of Recommendations in Included Guidelines ..................................................................... 43
List of Figures

Figure 1: Selection of Included Studies ................................................................. 19
Abbreviations

AE adverse event
AHSCT autologous hematopoietic stem cell transplantation
ALZ alemtuzumab
ARR annualized relapse rate
ASBMT American Society for Blood and Marrow Transplantation
CI confidence interval
CNS central nervous system
DMT disease-modifying therapy
EBMT European Society for Blood and Marrow Transplantation
EDSS Expanded Disability Status Scale
Gd gadolinium
IR incidence rate
MS multiple sclerosis
MSFC Multiple Sclerosis Functional Composite
MTX mitoxantrone
NEDA no evidence of disease activity
NRS Neurologic Rating Scale
PML progressive multifocal leukoencephalopathy
PPMS primary-progressive multiple sclerosis
RCT randomized controlled trial
RRMS relapsing-remitting multiple sclerosis
SF-36 QoL Short Form 36 (health survey) quality of life
SPMS secondary-progressive multiple sclerosis
Key Messages

- Evidence from 2 randomized controlled trials and 4 retrospective studies with limited methodological quality suggests that treatment with autologous hematopoietic stem cell transplantation was associated with significant improvement in clinical outcomes (e.g., disease progression, clinical relapse), MRI outcomes, the composite outcome “No Evidence of Disease Activity,” and quality of life compared to disease-modifying therapies.
- Treatment with autologous hematopoietic stem cell transplantation was associated with no treatment-related mortality or life-threatening complications including progressive multifocal leukoencephalopathy. However, autologous hematopoietic stem cell transplantation was associated with expected short-term adverse events including febrile neutropenia, organ infections, sepsis, and viral reactivations; and long-term adverse events including the development of new autoimmune diseases, mainly thyroid disease.
- Both identified guidelines recommend the use of autologous hematopoietic stem cell transplantation as standard of care for the treatment of highly active relapsing-remitting multiple sclerosis patients refractory to disease-modifying therapies and suggest that the treatment may be appropriate for progressive forms of multiple sclerosis with an active inflammatory component.
- No cost-effectiveness studies were identified.

Context and Policy Issues

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disorder of the central nervous system (CNS) that is more common in women than in men by a factor of approximately 3 to 1. One in every 400 Canadians live with MS and more than 4,000 people are diagnosed with MS every year. MS is heterogeneous in clinical course and can be classified into 4 subtypes: clinically isolated syndrome, relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), and secondary-progressive MS (SPMS). Clinically isolated syndrome is a first episode of inflammation of the CNS that is a characteristic of MS but does not meet the criteria for the diagnosis of MS. The diagnosis of MS has been revised by the McDonald Criteria published in 2017 by the International Panel on the Diagnosis of Multiple Sclerosis. Biomarkers for MS on MRI are gadolinium (Gd)-enhancing lesions and new T2 or enlarging T2 lesions, which are indicators of ongoing CNS inflammation. Approximately 85% to 90% of MS patients have RRMS, which is characterized by clearly defined periods of neurologic symptoms (relapses) alternating with periods of partial or complete recovery (remissions). Relapses occur when the immune system attacks the myelin sheet of the nerve fibres, causing an acute inflammation of the CNS. Patients with RRMS will eventually transition to SPMS, which is characterized by a progressive worsening of neurologic function over time. Some patients develop PPMS, characterized by progressive disability from the onset of symptoms independent of relapses.

There are currently more than a dozen of disease-modifying therapies (DMTs) for MS approved in Canada that are grouped into 3 categories: injectable medications (e.g., interferon beta-1a, interferon beta-1b, glatiramer acetate, ocrelizumab, peginterferon beta-1a), oral medications (e.g., teriflunomide, fingolimod, cladribine, siponimod, dimethyl fumarate, ozanimod), and infused medications (e.g., alemtuzumab, ocrelizumab, natalizumab). These
drugs have different mechanisms of action in modulating or suppressing the immune system, thereby reducing the disease activity and slowing down the rate of disability development. However, some patients with aggressive MS still show no improvement or have significant side effects after treatment with 1 or more approved DMTs.

Autologous hematopoietic stem cell transplantation (AHSCT) may be considered as a suitable immune reconstitution therapy for some MS patients at the early stage of disease when the inflammation is predominant and the disability level is low. AHSCT has been used for the treatment of MS for more than 2 decades. With improving techniques and expertise of transplantation, together with properly selected patients, the efficacy and safety of AHSCT have improved over time. AHSCT procedures consist of 5 main stages such as mobilization of hematopoietic stem cells using growth factor and chemotherapy, collection of stem cells from peripheral blood, conditioning chemotherapy to suppress immune system, reinfusion of stem cells, and support with blood products and antibiotics as well as follow-up with regular blood tests and medication. The conditioning regimens are classified based on the grade of intensity: high intensity, intermediate intensity, and low intensity. The intermediate intensity is further divided into myeloablative and non-myeloablative, depending on the regimens, and have been used most commonly in MS. High-intensity regimens have been associated with serious adverse events (AEs), while low-intensity regimens have been less efficacious.

The aim of this report is to review the clinical effectiveness and cost-effectiveness of AHSCT for the treatment of MS. The report also reviews the evidence-based guidelines regarding the use of AHSCT for MS. This report will support a CADTH Early Assessment Bulletin on MS.

Research Questions
1. What is the clinical effectiveness of AHSCT for treatment of MS?
2. What is the cost-effectiveness of AHSCT for treatment of MS?
3. What are the evidence-based guidelines regarding AHSCT for individuals with MS?

Methods

Literature Search Methods
A limited literature search was conducted by an information specialist on key resources including MEDLINE and Embase via Ovid, the Cochrane Database of Systematic Reviews, the international HTA database, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy comprised both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were autologous hematopoietic cell transplant and MS. Search filters were applied to limit retrieval to health technology assessments, systematic reviews, meta-analyses, or network meta-analyses, any types of clinical trials or observational studies, economic studies, or guidelines. Comments, newspaper articles, editorials, conference abstracts, and letters were excluded. Where
possible, retrieval was limited to the human population. The search was also limited to English-language documents published between January 1, 2015 and March 24, 2021.

Selection Criteria and Methods
One reviewer screened citations and selected studies. In the first level of screening, titles and abstracts were reviewed and potentially relevant articles were retrieved and assessed for inclusion. The final selection of full-text articles was based on the inclusion criteria presented in Table 1.

Exclusion Criteria
Articles were excluded if they did not meet the selection criteria outlined in Table 1, or were published before 2015. Studies that involved allogenic donor stem cells or mesenchymal stem cells were excluded. Economic evaluations without conducting cost-effectiveness analysis were excluded. Guidelines with unclear methodology were also excluded.

Critical Appraisal of Individual Studies
The included publications were critically appraised by 1 reviewer using the following tools as a guide: the Downs and Black checklist\textsuperscript{13} for randomized and non-randomized studies, and the Appraisal of Guidelines for Research & Evaluation (AGREE) II instrument\textsuperscript{14} for guidelines. Summary scores were not calculated for the included studies; rather, the strengths and limitations of each included publication were described narratively.

Summary of Evidence

Quantity of Research Available
A total of 464 citations were identified in the literature search. Following the screening of titles and abstracts, 423 citations were excluded and 41 potentially relevant reports from

### Table 1: Selection Criteria

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Individuals with RRMS or other subtypes of MS</td>
</tr>
<tr>
<td>Intervention</td>
<td>AHSCT also known as AHCT and formerly known as autologous bone marrow transplant</td>
</tr>
<tr>
<td>Comparator</td>
<td>Q1 and Q2: Standard of care (e.g., DMT); different AHSCT regimen(s) (e.g., myeloablative vs. non-myeloablative). Q3: Not applicable</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Q1: Clinical effectiveness: (e.g., disability, progression free survival, quality of life, pain; safety Q2: Cost-effectiveness Q3: Recommendations regarding treatment eligibility and suitability of candidates to receive AHSCT</td>
</tr>
<tr>
<td>Study designs</td>
<td>HTA, SR, RCT, non-randomized studies, economic evaluations, evidence-based guidelines</td>
</tr>
</tbody>
</table>

AHCT = autologous hematopoietic cell transplant; AHSCT = autologous hematopoietic stem cell transplant; DMT = disease-modifying therapy; HTA = health technology assessment; MS = multiple sclerosis; RCT = randomized controlled trial; RRMS = relapsing-remitting MS; SR = systematic review.
the electronic search were retrieved for full-text review. No potentially relevant publications were retrieved from the grey literature search for full-text review. Of these potentially relevant articles, 33 publications were excluded for various reasons and 8 publications met the inclusion criteria and were included in this report. These comprised 2 randomized controlled trials (RCTs), 4 non-randomized studies, and 2 evidence-based guidelines. Appendix 1 presents the PRISMA flow chart of the study selection. Additional references of potential interest are provided in Appendix 5.

**Summary of Study Characteristics**
The detailed characteristics of the included primary studies (Table 2) and the European Society for Blood and Marrow Transplantation (EBMT) guideline and the American Society for Blood and Marrow Transplantation (ASBMT) guideline (Table 3) are presented in Appendix 2.

**Study Design**
Of the 6 included primary studies, 2 were RCTs and 4 were retrospective cohort studies. Both RCTs (1 phase III and 1 phase II) were open-label, multi-centre, parallel, 1:1 trials. Both reported sample size calculations to detect a clinically relevant treatment effect. The results in the phase III trial were analyzed using a per-protocol population and not the intention-to-treat population. Adjustment for multiple comparisons were not performed in both RCTs. None of the retrospective cohort studies reported a sample size calculation. One retrospective cohort study used multivariate analysis to account for differences in some baseline characteristics between groups, while the other 3 retrospective cohort studies did not identify and adjust for covariates in their analyses.

Both included guidelines were developed to update their previous guidelines on the recommendations of AHSCT on MS treatment. Evidence was identified from literature searches. The recommendations in both guidelines were developed by a panel of experts in AH SCT and MS. The EBMT guideline rated the evidence as I, II, or III based on the health benefits, side effects, and risks of AH SCT, as compared with non-cell transplant options. The strength of recommendations in the EBMT guideline were classified as S (standard of care), CO (clinical option), D (developmental), or GNR (generally not recommended) based on the level of evidence obtained. The ASBMT guideline did not rate the evidence or the strength of its recommendations. The method of recommendations development and evaluation was not clearly stated in the ASBMT guideline.

**Country of Origin**
The included primary studies were conducted by authors from US, Italy, and Sweden. The included guidelines were conducted by authors from countries in Europe, and from the US and Canada.

**Patient Population**
Patients in out of 6 primary studies were exclusively RRMS. The phase II RCT included patients with progressive MS (67%) and RRMS (33%). One study had a patient population consisting mainly of RRMS with a small percentage of patients with PPMS (1.2%) and SPMS (6.1%). The sample sizes of 6 included studies ranged from 21 to 271. The mean age of patients in the included studies was approximately 35 years, with the percent of females ranging from 60% to 79%. The mean disease duration ranged from 6 to 11 years and the mean baseline Expanded Disability Status Scale (EDSS) score (which measures the
progression or deterioration of MS) ranged from 2.5 to 6. The EDSS score ranges from 0 to 10 in 0.5-point increments from no neurologic disability (0) to worst neurologic disability (10).

The target populations in both guidelines are patients diagnosed with defined MS. The intended users of both guidelines are health care workers in the MS field working with transplant teams or considering the referral of patients.

Interventions and Comparators
AHSCT was the intervention in all the included studies classified as myeloablative or non-myeloablative based on the conditioning regimens. The comparators were DMT, mitoxantrone (MTX), and alemtuzumab (ALZ).

The intervention considered in the evidence-based guidelines was AHSCT for MS.

Outcomes
The outcomes considered in the included primary studies could be classified as clinical outcomes, MRI outcomes, and safety outcomes. The clinical outcomes consisted of disease progression (defined as an increase in EDSS score of at least 1 point on 2 evaluations 6 months apart after at least 1 year of treatment), clinical relapse (a neurologic symptom lasting more than 24 hours; not associated with infection, fever, or heat intolerance), the Neurologic Rating Scale (NRS; range 0 to 100 in 1-point increments from worst [0] to no [100] disability; minimal clinically important difference, 10), the Short Form-36 quality of life (SF-36 QoL; range, 1 to 100; higher scores indicate more favourable health state), and the Multiple Sclerosis Functional Composite (MSFC) score (which incorporates the timed 25-ft walk test, the Nine-Hole Peg Test [a measure of arm function], and the Paced Auditory Serial Addition Test [scored as the total number correct out of 60 possible, and data shown are % of correct answers]). The MRI outcomes were MRI T2-weighted lesion volume (reported as % change from baseline), new T2 MRI lesions, Gd-enhancing lesions on T1-weighted MRI. No evidence of disease activity (NEDA) was a composite outcome defined as no progression, no relapses, and no new or enlarging lesions on MRI. The safety outcomes included mortality, early AEs (within 100 days after treatment), late AEs (after 100 days of treatment), and serious AEs. The follow-up period was 3 years in 5 studies and 5 years in 1 study.

Both guidelines considered the efficacy and safety outcomes of AHSCT in MS in the development of recommendations. The EBMT guideline also considered the resources implications and other issues relevant to the implementation of AHSCT.

Summary of Critical Appraisal
All included primary studies were explicit in reporting (i.e., clearly described the objective of the study, the main outcomes, the characteristics of the participants, the interventions, differences in baseline characteristics between groups, and the main findings of the study). All studies provided estimates of the random variability (e.g., standard deviation or 95% confidence interval) in the data of the main outcome and actual P values for main outcomes. As 2 RCTs and 4 retrospective cohort studies with relatively small sample sizes, it was not applicable to determine if the participants were representative of the entire population from which they were recruited. However, the treatment settings were representative of the treatment received by most of the patients. Both RCTs were open-label, as it was not possible to perform blinding of participants, personnel, or outcome assessors. Allocation concealment was not reported in the RCTs. Sample size was determined in both RCTs.
but not in the retrospective cohort studies.\textsuperscript{18-21} The intervention and comparator groups in all included studies had the same follow-up. Appropriate statistical tests were used to assess the main outcomes, which were accurately measured. Three\textsuperscript{18,19,21} of 4 retrospective cohort studies did not identify or conduct any adjustment for potential confounders in the analyses from which the main findings were drawn. The findings in those studies were therefore considered as crude and less reliable. Overall, all studies, except for the phase III RCT,\textsuperscript{16} were of limited methodological quality.

Both included guidelines\textsuperscript{12,22} were explicit in scope and purpose (i.e., objectives, health questions, and populations) and had clear presentation (i.e., specific and unambiguous recommendations, different options for management of the condition or health issue, and easy to find key recommendations). Regarding stakeholder involvement, the guidelines clearly defined target users and the development groups; however, it was unclear if the views and preferences of the MS populations were sought. For rigour of development, both guidelines\textsuperscript{12,22} did not report details of systematic searches for evidence, criteria for selecting evidence, and methods of formulating the recommendations. Both guidelines considered health benefits, side effects, and risks in formulating the recommendations, were peer-reviewed before publication, and provided a procedure for updating. For applicability, the EBMT guideline\textsuperscript{12} was explicit in terms of facilitators and barriers to application, advice and/or tools on how the recommendations can be put into practice, resource (cost) implications, and monitoring and/or auditing criteria. For editorial independence, it was unclear if the funding bodies had any influence over the content of the guidelines. The competing interests of the guideline development group members were reported. Overall, both included guidelines appeared to be of acceptable methodological quality.

\textbf{Summary of Findings}

The main findings and authors’ conclusions of the primary studies\textsuperscript{16-21} (Table 6) and the recommendations of the guidelines\textsuperscript{12,22} (Table 7) are presented in Appendix 4.

\textbf{Clinical Effectiveness of AHSCT}

\textit{Disease Progression}

In the phase III RCT,\textsuperscript{16} the proportions of patients with disease progression at 1, 3, and 5 years of follow-up were significantly lower in the AHSCT group (1.9%, 5.2%, and 9.7%, respectively) compared to those in the DMT group (24.5%, 62.5%, and 75.3%, respectively); \( P < 0.001 \). The median time to disease progression of the AHSCT group could not be calculated because of too few events and the median time to disease progression in the DMT group was 24 months (range, 18 to 48 months) (hazard ratio = 0.07; 95\% confidence interval [CI], 0.02 to 0.24; \( P < 0.001 \)). The between-group difference in mean change in EDSS score from baseline to 1 year was \( -1.7 \), 95\% CI, \( -2.03 \) to \( -1.29 \); \( P < 0.001 \). The phase II RCT\textsuperscript{17} with a small sample size (\( N = 21 \)) reported no significant difference between the AHSCT and MTX groups in the proportions of patients with disease progression, or in the EDSS change. The unobserved differences between groups in disease progression were likely due to the low power of this trial. A retrospective cohort study by Zhukovsky et al.\textsuperscript{19} found that the EDSS changes from baseline to 1, 2, and 3 years of follow-up in the AHSCT group showed significant improvement compared to those in the ALZ group (\( P < 0.0001 \)). Another retrospective cohort study by Boffa et al.\textsuperscript{20} found that AHSCT promoted significant EDSS improvement compared with ALZ (\( P = 0.035 \)). The proportion of patients with confirmed improvement in EDSS scores was significantly higher in the AHSCT group compared to the DMT groups (44.4\% versus 6.1\%; \( P = 0.013 \)).\textsuperscript{21}
Clinical Relapse

In the phase III RCT, the proportions of patients with clinical relapse in the AHSCT group were significantly lower compared to those in the DMT group at all time points of follow-up (P < 0.001). The annualized relapse rate (ARR) reported in the phase II RCT was significantly lower in the AHSCT group compared to the MTX group (0.19 versus 0.60; rate ratio = 0.36; 95% CI, 0.15 to 0.88; P = 0.026). A retrospective study by Zhukovsky et al. also reported a significantly lower ARR in the AHSCT group compared to the ALZ group (0.04 versus 0.1; P = 0.03). Similarly, 2 other retrospective cohort studies also showed a significantly lower ARR in the AHSCT group compared to the ALZ group (0.05 versus 0.35; P = 0.02) and to DMT (0.0 versus 0.67; P < 0.0001).

Neurologic Rating Scale

In the phase III RCT, the mean change in NRS score from baseline to 1 year in the AHSCT group was + 8.8 (improved) and that in the DMT group was −1.6 (worsened). The between-group difference in mean change in NRS score was + 11.2; 95% CI, + 8.08 to + 14.29; P = 0.001, indicating significant improvement in favour of the AHSCT group compared to the DMT group.

SF-36 QoL

In the phase III RCT, the quality of life in the AHSCT group was improved (+ 19.5) but worsened in the DMT group (−3.4). The between-group difference in mean change in SF-36 QoL score from baseline to 1 year was + 23; 95% CI, + 17.6 to + 28.9; P < 0.001.

Multiple Sclerosis Functional Composite

In the phase III RCT, the mean change in MSFC score from baseline to 1 year in the AHSCT group was + 0.32 (improved) and in the DMT group was −0.31 (worsened). The between-group difference was + 0.61; 95% CI, + 0.28 to + 0.72; P < 0.001. There were significant improvements in the timed 25-feet walk and the 9-Hole Peg Test in the AHSCT group compared to the DMT group (P < 0.001). However, there was no significant difference in the Paced Auditory Serial Addition Test score between groups (P = 0.61).

MRI outcomes

In the phase III RCT, the mean change in MRI T2-weighted lesion volume from baseline to 1 year in the AHSCT group was −31.7% (improved) and in the DMT group was + 34.3% (worsened). The between-group difference was −66% (95% CI, −70.6 to −61.3); P < 0.001. The phase II RCT showed that the number of new T2 lesions over 4 years was significantly reduced in the AHSCT group compared to the MTX group (rate ratio = 0.21; 95% CI, 0.10 to 0.48; P = 0.00016). The result remained significant in all sensitivity analyses. No patients in the AHSCT group had Gd-enhancing lesions compared to 56% of the MTX patients, who had at least 1 Gd lesions during 4 years of follow-up (P = 0.029). A retrospective cohort study by Boffa et al. showed that AHSCT significantly reduced the risk of MRI activity compared to the ALZ (MRI-activity-free survival: 85% versus 59%; hazard ratio = 0.13; 95% CI, 0.03 to 0.59; P = 0.009).

No Evidence of Disease Activity

The post-hoc analysis of the phase III RCT showed that the proportions of patients reaching NEDA at 1, 3, and 5 years after randomization were significantly higher in the AHSCT group (98.1%, 90.3%, and 78.5%, respectively) compared to the DMT group (20.8%, 5.9%, and 3%, respectively); P > 0.001. Three retrospective cohort studies also found similar results.
in that the proportions of patients with NEDA were significantly higher in the AHSCT group compared to the ALZ group or DMT group at the end of follow-up.

**Safety**

Four studies reported no deaths occurring in either intervention group. One study reported 1 death in the AHSCT group due to suicide (incidence rate [IR] per 1,000 person-years = 1.7; 95% CI, 0.0 to 9.6) and 4 deaths in the ALZ group (2 suicides, 1 heart attack, 1 cytomegalovirus reactivation) (IR per 1,000 person-years = 8.6; 95% CI, 2.3 to 22.0).

The phase III RCT reported that no AHSCT patients developed Common Toxicity Criteria grade 4 nonhematopoietic toxicities such as myocardial infarction, embolism, dialysis, sepsis, or need for pressor support. There were also no patients in the AHSCT group transferred to intensive care units; or who received parenteral nutrition, surgery, or other disabling or potential life-threatening events. Of the 52 study participants in the AHSCT group, few patients had inpatient grade 3 AE infections: there was 1 case (1.9%) of *Clostridium difficile* diarrhea, 1 case (1.9%) of *Escherichia coli* urinary tract infection, and 1 case (1.9%) of culture-negative pneumonia. Post-transplantation infections were mainly upper respiratory tract infections that occurred in both groups (16 cases [31%] in AHSCT group and 15 cases [29%] in DMT group). There was no progressive multifocal leukoencephalopathy (PML) caused by John Cunningham virus infections in either group. The rate of infection per patient-year was 0.19 in the AHSCT group and 0.23 in the DMT group. No statistical comparison between groups was given.

In the phase II RCT, early adverse events (occurring < 100 days after treatment) associated with AHSCT included grade 3 AEs, which included febrile neutropenia, leukopenia, anemia, platelet count decrease, amenorrhea, leukopenia; and grade 4 AEs, which included leukopenia, anemia, and platelet count decrease. In the MTX group, grade 3 AEs that occurred included neutrophil count decrease, amenorrhea, leukopenia, and lymphocyte count decrease; and grade 4 AEs that occurred included neutrophil count decrease. Severe AEs that occurred in the AHSCT group were sepsis, prolonged hospitalization, systemic candidiasis, cytomegalovirus reactivation, and engraftment failure. None of the patients in the MTX group had severe AEs. All AEs in the AHSCT group were resolved without sequelae. The IR of these AEs and statistical comparisons between groups were not provided.

A retrospective cohort study by Alping et al. found that thyroid disease occurred more often for AHSC (IR per 1,000 person-years = 34; 95% CI, 18 to 56) compared to the non-induction therapy group (natalizumab, dimethyl fumarate, rituximab, fingolimod) (IR = 5.3; 95% CI, 3.9 to 7.1), but less frequent than ALZ (IR = 109; 95% CI, 75 to 154). The non-thyroid autoimmune disease was rare, and the IRs were comparable between groups. The incidence of any infection was highest among the AHSCT group (IR = 275; 95% CI, 213 to 350) compared to ALZ group (IR = 56; 95% CI, 34 to 87) and the non-induction therapy group (IR = 52; 95% CI, 47 to 58), but dropped to the level near to the ALZ and the non-induction therapy groups within the first year. Common infections found after treatment with AHSCT and ALZ were herpes infections and bacterial sepsis. Systemic antibiotics were given to all patients after AHSCT and to most patients after ALZ. No cases of PML were detected.

A retrospective cohort study by Zhukovsky et al. reported that 70% of patients treated with AHSCT developed early Common Toxicity Criteria grade 3 AEs or higher in which febrile neutropenia (58%) was the most common. None of the patients in the ALZ group had grade 3 AEs or higher. Late grade 3 AEs occurred in 1 patient (1.4%) treated with AHSCT (Lyme neuroborreliosis) and 5 patients (6.7%) treated with ALZ (4 cases [5.3%] of immune mediated
thrombocytopenia, 1 case [1.3%] of breast cancer). Thyroid disease was the most common autoimmune adverse event that occurred in both groups: 20% in the AHSCT group and 47% in the ALZ group; P = 0.005. Herpes zoster infection developed in 5.8% in the AHSCT group and 6.7% in the ALZ group as late infection.

A retrospective cohort study by Boffa et al. reported that serious infections including neutropenic fever (64%) and sepsis (32%) were commonly diagnosed as early AEs in the AHSCT group. Late AEs such as autoimmune disorders, especially thyroid disorders, were more common in the ALZ group (28%) compared to the AHSCT group (4%).

A retrospective cohort study by Mariottini et al. found no life-threatening complications including PML after AHSCT. All infections and viral reactivations occurred within 1 year from transplantation. One patient in the AHSCT group (9%) developed autoimmune thyroiditis.

Cost-Effectiveness of AHSCT
No comparative cost-effectiveness studies of AHSCT were identified; therefore, no summary can be provided.

Guidelines
The EBMT guideline recommends that AHSCT should be offered to patients with RRMS who have high clinical and MRI inflammatory disease activity despite the use of 1 or more lines of approved DMTs. Patients should be younger than 45 years, with a EDSS score of 5.5, at most, and have a disease duration of less than 10 years. The strength of recommendation was categorized as S (standard of care) based on level I evidence. The guideline recommends that AHSCT should be considered for patients with "aggressive" MS who develop severe disability in the previous 12 months, even before failing a full course of DMT. The guideline suggests that SPMS, PPMS, and MS pediatric patients with documented evident disability progression in the previous 12 months should be considered for AHSCT, preferably in a prospective clinical trial. The strength of these recommendations was categorized as CO based on level II evidence. Details of the levels of evidence and strengths of recommendation are presented in the footnotes of Table 3 in Appendix 2.

The ASBMT guideline endorses AHSCT as "standard of care, with clinical evidence available" for patients with relapsing forms of MS (such as RRMS or progressive MS) who are refractory to treatment and have prognostic factors indicating a high risk of disability. This includes a clinical relapse and MRI activity, despite treatment with high efficacy MDTs. The strength of recommendation and the level of evidence were not given.

Limitations
The evidence from this review was derived from the findings of 2 RCTs and 4 retrospective cohort studies with relatively small sample sizes. Both RCTs were open-label by design because of the nature of the interventions that might result in a high risk of performance and detection biases. The study design of the phase III RCT allowed DMT patients to cross over to receive AHSCT after 1 year of follow-up in the event of treatment failure, resulting in up to 61% of DMT patients crossing over and thus limiting accurate comparisons of longer-term outcomes between groups. Two newer potent monoclonal antibodies — ocrelizumab and ALZ — were not included in the DMT group because of their unavailability or a safety concern that may result in a higher efficacy of AHSCT than their comparators. The phase III RCT used a per-protocol population in its analysis, which did not account for patients who were
lost to follow-up after treatment. Adjustment for multiple comparisons were not performed in both RCTs. The results of the retrospective non-randomized studies\textsuperscript{18-21} might be affected by selection bias because of the nature of the study design. None of the retrospective cohort studies reported sample size calculations. There were significant differences between groups in certain patient characteristics, such as age, disease duration, ARR, EDSS, MS type, and MRI activity at baseline. Patients in the ASHCT group were younger and had longer disease duration and higher disease activity compared to those in the control group. Three studies\textsuperscript{18,19,21} did not attempt to adjust for confounders in the analyses. As most patients in the included studies were of RRMS type, evidence for the clinical effectiveness of AHSCT on progressive MS remains to be determined. Both guidelines were limited in terms of rigour of development, as the details of systematic searches for evidence, criteria for selecting evidence, and methods of formulating the recommendations were not reported. However, the guidelines were the updated versions of their previous ones and were developed in Europe, the US, and Canada. Despite these limitations, all included studies showed profound effects of AHSCT in halting disease activity and preventing disability in RRMS patients. The findings of the clinical studies and the recommendations of the guidelines are likely to be applicable to the Canadian context.

Conclusions and Implications for Decision- or Policy-Making

Two RCTs\textsuperscript{16,17} and 4 retrospective cohort studies\textsuperscript{18-21} were included to address the clinical effectiveness of AHSCT in patients with MS. Two evidence-based guidelines\textsuperscript{12,22} on the use of AHSCT in MS were identified. No studies regarding the cost-effectiveness of AHSCT for MS were identified.

Compared to ALZ or other DMTs, patients in the AHSCT group had significant improvement in clinical outcomes including disease progression, clinical relapse, NRS, MSFC score, and NEDA. Patients treated with AHSCT also experienced improvement in quality of life and a decrease in MRI activity such as new T2 lesions and Gd-enhancing lesions. For safety, there was no treatment-related mortality or life-threatening complications including PML after treatment with AHSCT. The most common AEs in the first 100 days after AHSCT treatment were febrile neutropenia, organ infections, sepsis and viral reactivations (e.g., Epstein-Barr virus, cytomegalovirus, varicella-zoster virus). Long-term AEs included the development of new autoimmune diseases, mainly thyroid disease. Studies comparing different AHSCT conditioning regimens such as myeloablative and non-myeloablative were not identified. Thus, AHSCT appears to be efficacious with expected adverse events. Treatment with DMTs including ALZs and MTZ were also associated with high rates of infection. Thyroid disease occurred more frequent in the patients treated with ALZ compared to AHSCT patients. The identified guidelines recommend the use of AHSCT as standard of care for the treatment of highly active RRMS patients refractory to DMTs and suggest that the treatment may be appropriate for progressive forms of MS with an active inflammatory component. As the follow-up period was 3 years in most included studies, longer-term efficacy and safety data of AHSCT remain to be determined. The findings in this report should be interpreted with caution because of some limitations of the included studies (e.g., small sample sizes, and limited in study design). Future large and well-designed RCTs with inclusion of more recent and potent DMTs are warranted to further evaluate the role of AHSCT in MS with longer-term efficacy and
safety data. Moreover, trials aiming at refining treatment procedure by comparing different conditioning regimens are also needed.
References


Appendix 1: Selection of Included Studies

Figure 1: Selection of Included Studies

464 citations identified from electronic literature search and screened

423 citations excluded

41 potentially relevant articles retrieved for scrutiny (full text, if available)

0 potentially relevant reports retrieved from other sources (grey literature, handsearch)

41 potentially relevant reports

33 reports excluded:
- irrelevant population (2)
- irrelevant intervention (2)
- irrelevant comparator (7)
- irrelevant outcomes (2)
- irrelevant design (4)
- published in language other than English (2)
- other (review articles, editorials) (14)

8 reports included in review
Appendix 2: Characteristics of Included Publications

Table 2: Characteristics of Included Primary Clinical Studies

<table>
<thead>
<tr>
<th>Study citation, country, funding source</th>
<th>Study design</th>
<th>Population characteristics</th>
<th>Intervention and comparator(s)</th>
<th>Clinical outcomes, length of follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burt et al., 2019&lt;sup&gt;16&lt;/sup&gt; US</td>
<td>Phase III, open-label, multicenter, parallel, 1:1 RCT</td>
<td>Patients with RRMS (N = 110)</td>
<td>Non-myeloablative HSCT (n = 55): DMT was discontinued and variable washout periods were observed before admission for HSCT. DMT (n = 55): Received an FDA-approved DMT of higher efficacy or a different class than the therapy taken at the time of randomization. Could also receive immune-modulating or immunosuppressive drugs. Ocrelizumab and alemtuzumab were excluded. Patients experiencing progression of disability after at least 1 year of treatment were allowed to cross over to receive HSCT.</td>
<td>Primary Outcome: Disease progression (an increase in EDSS score of at least 1 point on 2 evaluations 6 months apart after at least 1 year of treatment)</td>
</tr>
<tr>
<td>Funding: No industry support or pharmaceutical support</td>
<td>Sample size determination: Yes</td>
<td>Mean age, years:</td>
<td></td>
<td>Secondary Outcomes:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• HSCT: 35.6</td>
<td>• Survival</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DMT: 35.6</td>
<td>• Relapses (a neurologic symptom lasting &gt; 24 hours; not associated with infection, fever, or heat intolerance)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>% female:</td>
<td>• NRS (range 0 to 100 in 1-point increments from worst [0] to no [100] disability; MCID, 10)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• HSCT: 62</td>
<td>• T2-weighted lesion volume (% change from baseline)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DMT: 66</td>
<td>• SF-36 QoL (range 1 to 100; higher scores = more favourable health state)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mean duration of disease, months:</td>
<td></td>
<td>• MSFC score (incorporates a timed 25-ft walk test, the 9-Hole Peg test [a measure of arm function], and the PASAT [scored as the total number correct out of 60; data shown are % of correct answers])</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• HSCT: 63.1</td>
<td></td>
<td>Post-hoc Outcomes:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• DMT: 84.8</td>
<td></td>
<td></td>
<td>• Time to first relapse</td>
</tr>
<tr>
<td></td>
<td>Mean EDSS:</td>
<td></td>
<td></td>
<td>• NEDA (i.e., no progression, no relapses, and no new or enlarging lesions on MRI)</td>
</tr>
<tr>
<td></td>
<td>• HSCT: 3.4</td>
<td></td>
<td></td>
<td>• Outcomes of patients in DMT group who crossed over to receive HSCT</td>
</tr>
<tr>
<td></td>
<td>• DMT: 3.3</td>
<td></td>
<td></td>
<td>Adverse events: Transplantation-related; hospitalizations; ED visits; infections; new medical problems</td>
</tr>
<tr>
<td></td>
<td>Mean number of Gd-enhancing lesions on MRI:</td>
<td></td>
<td>Follow-up: 5 years</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• HSCT: 4.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• DMT: 4.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mean MRI T2-weighted lesion volume, cm³:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• HSCT: 16.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• DMT: 12.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study citation, country, funding source</td>
<td>Study design</td>
<td>Population characteristics</td>
<td>Intervention and comparator(s)</td>
<td>Clinical outcomes, length of follow-up</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-------------</td>
<td>---------------------------</td>
<td>--------------------------------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>Mancardi et al., 2015&lt;sup&gt;17&lt;/sup&gt; Italy Funding: Italian Multiple Sclerosis Foundation</td>
<td>phase II, open-label, multicenter, parallel, 1:1 RCT Sample size determinations: Yes ITT analysis: Yes Adjustment for multiple comparison: No</td>
<td>Patients with a defined MS (secondary-progressive MS or RRMS) (N = 21) Mean age, years: • AHSCT: 36 • MTX: 35 % female: • AHSCT: 56 • MTX: 75 Median EDSS (range) • AHSCT: 6.5 (5.5 to 6.5) • MTX: 6 (5.5 to 6.5) Mean disease duration (range), years: • AHSCT: 10.5 (5 to 20) • MTX: 9.8 (2 to 23)</td>
<td>Myeloablative AHSCT (n = 9) MTX (n = 12): 20 mg every month for 6 months</td>
<td>Primary Outcomes: • Number of new T2 MRI lesions Secondary Outcomes: • Gd-enhancing lesions on T1-weighted MRI • Relapses • Time to disability progression • Time of appearance of the first new T2 MRI lesions Safety: • AHSCT-related mortality • Early AEs • Serious AEs Follow-up: 4 years</td>
</tr>
<tr>
<td>Alping et al., 2021&lt;sup&gt;18&lt;/sup&gt; Sweden Funding: Patient-Centered Outcomes Research Institute award.</td>
<td>Retrospective cohort study Sample size determination: No Adjustment for covariates: No</td>
<td>Patients with MS (mainly RRMS) (N = 271) Mean age, years: 34.0 % female: 65.0 Mean MS duration, years: 6.7 MS type, %: • RRMS: 92.8 • PPMS: 1.2 • SPMS: 6.1 Mean EDSS score: 3.1</td>
<td>Both non-myeloablative and myeloablative AHSCT (n = 139) ALZ (n = 132) Matched non-induction therapies (Natalizumab, dimethyl fumarate, rituximab, fingolimod; n = 2,486)</td>
<td>Outcomes: • Death • Thyroid disease • Non-thyroid autoimmune disease • Infection Follow-up: 3 years</td>
</tr>
<tr>
<td>Study citation, country, funding source</td>
<td>Study design</td>
<td>Population characteristics</td>
<td>Intervention and comparator(s)</td>
<td>Clinical outcomes, length of follow-up</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-------------</td>
<td>---------------------------</td>
<td>-------------------------------</td>
<td>----------------------------------------</td>
</tr>
</tbody>
</table>
| Zhukovsky et al., 2021, Sweden         | Retrospective cohort study | Patients with RRMS treated with AH SCT or alemtuzumab from 1 January 2011 to 31 December 2018 (N = 144) | Non-myeloablative AH SCT (n = 69) ALZ (n = 75): 60 mg over 5 days and a repeated dose of 36 mg over 3 days after 1 year. New courses of 36 mg were administered if clinical relapses and/or new MRI lesions occurred. | Primary Outcomes:  
  - NEDA at 3 years (defined as absence of clinical relapses, CDW and MRI events) |
| Funding: No industry support or pharmaceutical support | Sample size determination: No | Median age (IQR):  
  - AH SCT: 30 (26 to 37)  
  - ALZ: 35 (30 to 41); P = 0.005 | | Secondary Outcomes:  
  - Freedom from MRI events  
  - Clinical relapses (a period of acute worsening of neurologic function lasting ≥ 24 hour not attributable to an external cause such as increased body temperature or acute infection)  
  - Freedom from CDW (an increase in EDSS score with at least 1 point from baseline sustained between 2 follow-up visits separated in time by no less than 6 months)  
  - ARR (number of relapses occurring during a time period divided by the number of years in that time period)  
  - Proportion of patients (EDSS ≥ 2) with CDI/stability/CDW (CDI, a decrease in EDSS score with at least 1 point from baseline sustained between 2 follow-up visits separated in time by no less than 6 months)  
  - AEs of grade 3 or higher according to CTCAE v5.0 within the first 100 days after treatment  
  - Late AEs after treatment (autoimmune or infectious AEs grade 2 or higher, or any AEs grade 3 or higher present at 100 days from treatment or occurring thereafter. | | |
| | Adjustment for covariates: No | % female:  
  - AH SCT: 40.8  
  - ALZ: 78.6 | | Follow-up: 3 years |
<table>
<thead>
<tr>
<th>Study citation, country, funding source</th>
<th>Study design</th>
<th>Population characteristics</th>
<th>Intervention and comparator(s)</th>
<th>Clinical outcomes, length of follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boffa et al., 2020&lt;sup&gt;20&lt;/sup&gt; Italy Funding: Did not receive any funding support</td>
<td>Retrospective cohort study Sample size determination: No Adjustment for covariates: Yes</td>
<td>Patients with aggressive RRMS (multiple ≥ 2 relapses with incomplete resolution in the past year; &gt; 2 MRI scans showing new or enlarging T2 lesions or Gd-enhancing lesions despite active treatment; or EDSS score ≥ 4 within 5 years of onset; no response to therapy with 1 or more DMTs for up to 1 year) (N = 57) Mean age, years:  • AHSCT: 32.1, ALZ: 35.1 % female:  • AHSCT: 76, ALZ: 75 Median EDSS (IQR):  • AHSCT: 6 (4.5 to 7), ALZ: 3 (1 to 4) Mean disease duration, years:  • AHSCT: 9.5, ALZ: 7.2 Mean ARR:  • AHSCT: 3.2, ALZ: 1.7 MRI activity, %:  • AHSCT: 88, ALZ: 44 Mean number of Gd-enhancing lesions:  • AHSCT: 15.5, ALZ: 1.6 Mean follow-up, months:  • AHSCT: 50.9, ALZ: 26.3</td>
<td>Myeloablative AHSCT (n = 25) ALZ (n = 32): 12 mg per day on 5 consecutive days and the second of 12 mg per day on 3 consecutive days, 12 months apart.</td>
<td>Outcomes:  Primary:  • Time to first relapse  • Time to confirm disability worsening  • Time to first evidence of MRI activity  • Time to first evidence of disease activity (according to NEDA definition) Secondary:  • ARR at 12, 24 and 36 months  • 6-month confirmed EDSS changes at 12 and 24 months  • Safety  Follow-up: 3 years</td>
</tr>
<tr>
<td>Study citation, country, funding source</td>
<td>Study design</td>
<td>Population characteristics</td>
<td>Intervention and comparator(s)</td>
<td>Clinical outcomes, length of follow-up</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-------------</td>
<td>-----------------------------</td>
<td>-------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Mariottini et al., 2019&lt;sup&gt;21&lt;/sup&gt; Italy Funding: Not reported</td>
<td>Retrospective cohort study</td>
<td>Patients with RRMS who discontinued from natalizumab after at least 6 administrations and with at least 6 months of follow-up (N = 55)</td>
<td>Myeloablative AHSCT (n = 11) DMT (n = 41): First-line (interferons, glatiramer acetate, dimethyl fumarate) or second-line (fingolimod, alemtuzumab, rituximab, cyclophosphamide, mitoxantrone)</td>
<td>Outcomes: • NEDA • Clinical relapses • Disability worsening • Safety (AEs) Follow-up: 3 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Median age (IQR), years:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• AHSCT: 35 (31 to 43)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DMT: 39 (35 to 47)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>% female:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• AHSCT: 81.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DMT: 75.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Median disease duration (IQR), years:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• AHSCT: 13.0 (5.0 to 16.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DMT: 9.0 (5.0 to 13.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Median EDSS score (IQR):</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• AHSCT: 3.0 (1.5 to 4.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DMT: 2.5 (2.4 to 4.0)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AE = adverse event; AHSCT = autologous hematopoietic stem cell transplantation; ALZ = alemtuzumab; ARMSS = age-related multiple sclerosis severity score; ARR = annualized relapse rate; CDI = confirmed disability improvement; CDW = confirmed disability worsening; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; FDA = FDA; Gd = gadolinium; HSCT = hematopoietic stem cell transplantation; IQR = interquartile range; ITT = intention-to-treat; MCID = minimal clinically important difference; MRI = MRI; MSFC = Multiple Sclerosis Functional Composite; MTX = mitoxantrone; MS = multiple sclerosis; NEDA = no evidence of disease activity; NRS = Neurologic Rating Scale; PASAT = Paced Auditory Serial Addition Test; PPMS = primary-progressive MS; QoL = quality of life; RCT = randomized controlled trial; RRMS = relapse-remitting multiple sclerosis; SF-36 = Short Form 36; SPMS = secondary-progressive MS.
### Table 3: Characteristics of Included Guidelines

<table>
<thead>
<tr>
<th>Intended users, target population</th>
<th>Intervention and practice considered</th>
<th>Major outcomes considered</th>
<th>Evidence collection, selection, and synthesis</th>
<th>Evidence quality assessment</th>
<th>Recommendations development and evaluation</th>
<th>Guideline validation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intended users: Transplant physicians, nurses, neurologists Target population: Not primarily targeted at patients, families, and non-specialist health professional carers</td>
<td>HSCT in MS and immune-mediated neurologic diseases</td>
<td>Efficacy and safety of AHSCT</td>
<td>Evidence was found from PubMed searches and recent EBMT congress presentations. Evidence selection and synthesis: Not reported</td>
<td>Evidence levels (I, II, III)(^a) based on consideration of health benefits, side effects and risks, and balanced against non-HSCT options. Recommendations(^b) were classified as S, CO, D or GNR</td>
<td>Updated of its previous guidelines Recommendations were developed by clinicians, nurses, statisticians and data management persons, all with experience in HSCT. Each recommendation provides potential for auditing clinical practice. The guideline considers resource implications and other issues relevant to implementations of HSCT.</td>
<td>Published in peer-reviewed journal</td>
</tr>
</tbody>
</table>

\(^a\)Evidence quality assessment processes were not described in this guideline. \(^b\)Recommendations grade was classified as S, CO, D or GNR.
### Intended Users, Target Population

**Intended Users:** Neurologists in treating MS and transplantation physicians with experience in AHSCT  
**Target Population:** Patients with MS  

### Evidence collection, selection, and synthesis

Evidence identified from the Embase and Ovid MEDLINE databases. One author reviewed all search results. Evidence selection and synthesis: Not reported.

### Evidence quality assessment

Evidence quality assessment: None, just by consensus from a panel of experts (expert opinion).

### Recommendations development and evaluation

Updated of its previous guidelines. Recommendations were developed by a panel of experts in AHSCT and MS.

### Guideline validation

Published in peer-reviewed journal.

---

**AHSCT** = autologous hematopoietic stem cell transplantation; **ASBMT** = American Society for Blood and Marrow Transplantation; **HSCT** = Hematopoietic stem cell transplantation; **EBMT** = European Group for Blood and Marrow Transplantation; **MS** = multiple sclerosis; **RCT** = randomized controlled trial.

Note that this table has been formatted for accessibility but has not been copy-edited.

---

**Levels of evidence:**

I: from at least one well-executed RCT.

II: from at least 1 well-designed clinical trial without randomization; cohort or case-controlled analytic studies (preferably from more than 1 centre); multiple time-series studies; or dramatic results from uncontrolled experiments.

III: from opinions of respected authorities based on clinical experience, descriptive studies, or reports from expert committees.

**Recommendations:**

S: Standard of care – Indications categorized as S are reasonably well defined and results compare favourably (or are superior) to those of non-transplant treatment approaches.

CO: clinical option – The CO category applies to indications for which the results of small patient cohorts show efficacy and acceptable toxicity of the HSCT procedure, but confirmatory randomized studies are missing, often as a result of low patient numbers.

D: Developmental – Indications have been classified as D when the experience is limited, and additional research is needed to define the role of HSCT.

GNR = Generally not recommended – The GNR category comprises a variety of clinical scenarios in which the use of HSCT cannot be recommended to provide a clinical benefit to the patient, including early disease stages when results of conventional treatment do not normally justify the additional risk of a HSCT; very advanced forms of a disease in which the chance of success is so small that does not justify the risks for patient and donor, and indications in which the transplant modality may not be adequate for the characteristics of the disease.
## Appendix 3: Critical Appraisal of Included Publications

Note that this appendix has not been copy-edited.

### Table 4: Strengths and Limitations of Clinical Studies Using the Downs and Black Checklist\(^\text{13}\)

<table>
<thead>
<tr>
<th>Item</th>
<th>Burt et al., 2019(^\text{16})</th>
<th>Mancardi et al., 2015(^\text{17})</th>
<th>Alping et al., 2021(^\text{18})</th>
<th>Zhukovsky et al., 2021(^\text{19})</th>
<th>Boffa et al., 2020(^\text{20})</th>
<th>Mariottini et al., 2019(^\text{21})</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reporting</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Is the hypothesis/aim/objective of the study clearly described?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>2. Are the main outcomes to be measured clearly described in the Introduction or Methods section?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>3. Are the characteristics of the patients included in the study clearly described?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>4. Are the interventions of interest clearly described?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>5. Are the distributions of principal confounders in each group of subjects to be compared clearly described?</td>
<td>NA – RCT, characteristic balanced between groups</td>
<td>NA – RCT, characteristic balanced between groups</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>NA – characteristic balanced between groups</td>
</tr>
<tr>
<td>6. Are the main findings of the study clearly described?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>7. Does the study provide estimates of the random variability in the data for the main outcomes?</td>
<td>Yes – 95% CI provided</td>
<td>Yes – 95% CI provided</td>
<td>Yes – 95% CI provided</td>
<td>Yes – 95% CI provided</td>
<td>Yes – 95% CI provided</td>
<td>Yes – interquartile range provided</td>
</tr>
<tr>
<td>8. Have all important adverse events that may be a consequence of the intervention being reported?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes – mainly reported on safety data</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Item</td>
<td>Burt et al., 2019</td>
<td>Mancardi et al., 2015</td>
<td>Alping et al., 2021</td>
<td>Zhukovsky et al., 2021</td>
<td>Boffa et al., 2020</td>
<td>Mariottini et al., 2019</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------------------</td>
<td>-----------------------</td>
<td>---------------------</td>
<td>-----------------------</td>
<td>---------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>9. Have the characteristics of patients lost to follow-up been described?</td>
<td>No</td>
<td>NA – no patients lost to follow-up</td>
<td>NA – retrospective study</td>
<td>NA – retrospective study</td>
<td>NA – retrospective study</td>
<td>NA – retrospective study</td>
</tr>
<tr>
<td>Item</td>
<td>Burt et al., 2019&lt;sup&gt;16&lt;/sup&gt;</td>
<td>Mancardi et al., 2015&lt;sup&gt;17&lt;/sup&gt;</td>
<td>Alping et al., 2021&lt;sup&gt;18&lt;/sup&gt;</td>
<td>Zhukovsky et al., 2021&lt;sup&gt;19&lt;/sup&gt;</td>
<td>Boffa et al., 2020&lt;sup&gt;20&lt;/sup&gt;</td>
<td>Mariottini et al., 2019&lt;sup&gt;21&lt;/sup&gt;</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>-----------------------------------</td>
<td>----------------------------------</td>
<td>---------------------------------</td>
<td>---------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>If any of the results of the study were based on “data dredging”, was this made clear?</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>In trials and cohort studies, so the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is the time period between the intervention and outcome the same for cases and controls?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Were the statistical tests used to assess the main outcomes appropriate?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Was compliance with the intervention/s reliable?</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Were the main outcome measures used accurate (valid and reliable)?</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Internal validity – confounding (selection bias)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited from the same population?</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes – From the Swedish Multiple Sclerosis Register</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Were study subjects in different intervention groups (trial and cohort studies) or were the cases and controls (case-controls studies) recruited over the same period of time?</td>
<td>Yes – between 2005 to 2016</td>
<td>Yes</td>
<td>Yes – between 1 January 2011 to 31 December 2018</td>
<td>Unclear</td>
<td>Yes – between January 2010 to June 2016</td>
<td></td>
</tr>
<tr>
<td>Item</td>
<td>Burt et al., 2019(^{15})</td>
<td>Mancardi et al., 2015(^{17})</td>
<td>Alping et al., 2021(^{18})</td>
<td>Zhukovsky et al., 2021(^{19})</td>
<td>Boffa et al., 2020(^{20})</td>
<td>Mariottini et al., 2019(^{21})</td>
</tr>
<tr>
<td>---------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>-------------------------------</td>
<td>-----------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>23. Were study subjects randomized to intervention groups?</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>24. Was the randomized intervention assignment concealed from both patients and health care staff until recruitment was complete and irrevocable?</td>
<td>Unclear</td>
<td>Unclear</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>25. Was the adequate adjustment for confounding in the analyses from which the main findings were drawn?</td>
<td>NA – RCT</td>
<td>NA – RCT</td>
<td>No</td>
<td>No</td>
<td>Yes – multivariate analysis</td>
<td>No</td>
</tr>
<tr>
<td>26. Were losses of patients to follow-up taken into account?</td>
<td>No – no ITT analysis</td>
<td>NA – all patients were follow-up</td>
<td>NA – retrospective study</td>
<td>NA – retrospective study</td>
<td>NA – retrospective study</td>
<td>NA – retrospective study</td>
</tr>
<tr>
<td>27. Did the study have sufficient power to detect a clinically important effect where the P value for a difference being due to chance is less than 5%?</td>
<td>Yes – sample size determination</td>
<td>Yes – sample size determination</td>
<td>No – no sample size determination</td>
<td>No – no sample size determination</td>
<td>No – no sample size determination</td>
<td>No – no sample size determination</td>
</tr>
</tbody>
</table>

ITT = intention-to-treat; NA = not applicable; RCT = randomized controlled trial.
<table>
<thead>
<tr>
<th>Item</th>
<th>EBMT, Sharrack et al., 2020¹²</th>
<th>ASBMT, Cohen et al., 2019²²</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Domain 1: Scope and Purpose</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. The overall objective(s) of the guideline is (are) specifically described.</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>2. The health question(s) covered by the guideline is (are) specifically described.</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Domain 2: Stakeholder Involvement</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. The guideline development group includes individuals from all relevant professional groups.</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>5. The views and preferences of the target population (patients, public, etc.) have been sought.</td>
<td>Unclear</td>
<td>Unclear</td>
</tr>
<tr>
<td>6. The target users of the guideline are clearly defined.</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Domain 3: Rigour of Development</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Systematic methods were used to search for evidence.</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>8. The criteria for selecting the evidence are clearly described.</td>
<td>NR</td>
<td>Yes</td>
</tr>
<tr>
<td>9. The strengths and limitations of the body of evidence are clearly described.</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>10. The methods for formulating the recommendations are clearly described.</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>11. The health benefits, side effects, and risks have been considered in formulating the recommendations.</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>12. There is an explicit link between the recommendations and the supporting evidence.</td>
<td>Probably yes</td>
<td>Probably yes</td>
</tr>
<tr>
<td>13. The guideline has been externally reviewed by experts before its publication.</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>14. A procedure for updating the guideline is provided.</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Domain 4: Clarity of Presentation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15. The recommendations are specific and unambiguous.</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>16. The different options for management of the condition or health issue are clearly presented.</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>17. Key recommendations are easily identifiable.</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Domain 5: Applicability</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18. The guideline describes facilitators and barriers to its application.</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>19. The guideline provides advice and/or tools on how the recommendations can be put into practice.</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>20. The potential resource implications of applying the recommendations have been considered.</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>21. The guideline presents monitoring and/or auditing criteria.</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>
## Domain 6: Editorial Independence

<table>
<thead>
<tr>
<th>Item</th>
<th>EBMT, Sharrack et al., 2020&lt;sup&gt;12&lt;/sup&gt;</th>
<th>ASBMT, Cohen et al., 2019&lt;sup&gt;22&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>22. The views of the funding body have not influenced the content of the guideline.</td>
<td>Unclear</td>
<td>Unclear</td>
</tr>
<tr>
<td>23. Competing interests of guideline development group members have been recorded and addressed.</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

AGREE II = Appraisal of Guidelines for Research and Evaluation II; ASBMT = American Society for Blood and Marrow Transplantation; EBMT = European Group for Blood and Marrow Transplantation; NR = not reported; NA = not applicable.
Appendix 4: Main Study Findings and Authors’ Conclusions

Note that this appendix has not been copy-edited.

Summary of Findings of Included Primary Clinical Studies

Main study findings

*Burt et al., 2019*16

Non-myeloablative hematopoietic stem cell therapy (HSCT) (n = 55) versus DMT (n = 55)

Primary end point

Disease progression (EDSS score increase of ≥ 1):

- HSCT: 3 patients
- DMT: 34 patients
- Follow-up: median, 2 years; mean, 2.8 years

Median time to progression:

- HSCT: not estimable due to too few events
- DMT: 24 months (interquartile range [IQR], 18 to 48 months)
- hazard ratio (HR) (95% CI) = 0.07 (0.02 to 0.24); P < 0.001

Proportion of patients with disease progression:

- HSCT:
  - One year and 2 years: 1.92% (95% CI, 0.27 to 12.9)
  - Three years: 5.19% (95% CI, 1.26 to 20.1)
  - Four and 5 years: 9.71% (95% CI, 3.0 to 28.8)
- DMT:
  - One year: 24.5% (95% CI, 14.7 to 39.1)
  - Two years: 54.5% (95% CI, 40.7 to 69.4)
  - Three years: 62.5% (95% CI, 48.3 to 76.7)
  - Four years: 71.2% (95% CI, 56.8 to 84.2)
  - Five years: 75.3% (95% CI, 60.4 to 87.8)

Secondary end points

- Death:
  - HSCT: 0
  - DMT: 0

Relapse in the first year:

- HSCT: 2%
- DMT: 69%

Between-group difference: 78% (95% CI, 64 to 88); P < 0.001

Proportion of patients with relapse:
• HSCT:
  ◦ Six months: 0%
  ◦ One year: 1.92% (95% CI, 0.27 to 12.9)
  ◦ Two years: 7.69% (95% CI, 2.96 to 19.2)
  ◦ Three years: 9.61% (95% CI, 4.1 to 22)
  ◦ Four and 5 years: 15.4% (95% CI 8.01 to 28.4)
• DMT:
  ◦ Six months: 51.9% (39.9 to 65.6)
  ◦ One year: 64.8% (95% CI, 52.2 to 77.2)
  ◦ Two years: 72.2% (95% CI, 66 to 87.7)
  ◦ Three and 4 years: 79.63% (95% CI, 68.1 to 89.1)
  ◦ Five years: 85.2% (95% CI, 74.5 to 93.1)

Mean change in EDSS score from baseline to 1 year:
• HSCT: −1.02 (improved)
• DMT: + 0.67 (worsened)
• Between-group difference: −1.7 (95% CI, −2.03 to −1.29); P < 0.001

Mean change in NRS score from baseline to 1 year:
• HSCT: + 8.8 (improved)
• DMT: −1.6 (worsened)
• Between-group difference: + 11.2 (95% CI, + 8.08 to + 14.29); P = 0.001

Mean change in MRI T2-weighted lesion volume from baseline to 1 year:
• HSCT: −31.7% (improved)
• DMT: + 34.3% (worsened)
• Between-group difference: −66% (95% CI, −70.6 to −61.3); P < 0.001

Mean change in timed 25-feet walk from baseline to 1 year:
• HSCT: −0.5 second (improved)
• DMT: + 1.3 second (worsened)
• Between-group difference: −2.85 second (95% CI, −3.92 to −1.77); P < 0.001

Mean change in 9-Hole Peg Test from baseline to 1 year:
• HSCT: −6.8 second (improved)
• DMT: + 0.9 second (worsened)
• Between-group difference: −8.03 second (95% CI, −11.3 to −4.76); P < 0.001

Mean change in Paced Auditory Serial Addition Test from baseline to 1 year:
• HSCT: + 10.4% (improved)
• DMT: + 10.2% (improved)
• Between-group difference: + 0.22% (95% CI, −72.4 to + 72.9); P = 0.61

Mean change in MSFC score from baseline to 1 year:
• HSCT: +0.32 (improved)
• DMT: −0.31 (worsened)
• Between-group difference: +0.51 (95% CI, +0.28 to +0.72); P < 0.001
Mean change in SF-36 quality of life score from baseline to 1 year:
• HSCT: +19.5 (improved)
• DMT: −3.4 (worsened)
• Between-group difference: +23 (95% CI, +17.6 to +28.9); P < 0.001
Post-hoc analysis
Median time to first relapse:
• HSCT: not estimable due to too few events
• DMT: 6 months (IQR, 3 to 36 months)
• HR (95% CI) = 0.097 (0.045 to 0.208); P < 0.001
Proportion with NEDA:
• HSCT:
  ◦ Six months and 1 year: 98.1% (95% CI, 87.4 to 99.7)
  ◦ Two years: 93.3% (95% CI, 80.6 to 97.8)
  ◦ Three years: 90.3% (95% CI, 75.9 to 96.3)
  ◦ Four and 5 years: 78.5% (95% CI, 59.8 to 89.5)
• DMT:
  ◦ Six months: 39.6% (95% CI, 26.6 to 52.39)
  ◦ One year: 20.8% (95% CI, 11 to 32.5)
  ◦ Two years: 11.9% (95% CI, 4.3 to 23.6)
  ◦ Three years: 5.93 (95% CI, 1.17 to 16.6)
  ◦ Four and 5 years: 2.97% (95% CI, 0.24 to 12.8)
Outcomes of patients in the DMT groups who crossed over to HSCT:
• For 5 years after transplantation, 31 patients crossed over from DMT to HSCT. There was significant improvement in EDSS scores, NRS scores, and T2-weighted lesion volume percentages.
• The results of combined group (52 + 31 = 83 patients) who underwent HSCT were comparable with those for the HSCT group alone (n = 52 patients).
Adverse events:
• HSCT:
  • Median day of white blood cell engraftment (absolute neutrophil count > 1000/µL): 9 days
  • Hospital day: 10 days
  • No Common Toxicity Criteria grade 4 nonhematopoietic toxicity (e.g., myocardial infarction, embolism, dialysis, sepsis, or need for pressor support), transfer to intensive care unit, parenteral nutrition, surgery, or other disabling or potential life-threatening events.
  • Inpatient grade 3 toxicities infections: *Clostridium difficile* diarrhea (n = 1), *Escherichia coli* urinary tract infection (n = 1), culture-negative pneumonia (n = 1)
• Post-transplantation infections: 16 upper respiratory tract infections (7 sinusitis, 2 bronchitis, 2 undefined pneumonia, 2 streptococcal pharyngitis, 1 influenza, 1 respiratory syncytial virus, 1 Mycoplasma pneumoniae), 6 urinary tract infections, 2 C difficile diarrhea, and 7 dermatomal varicella-zoster reactivations.
• No early or late fungal, Pneumocystis jiroveci, cytomegalovirus, John Cunningham virus infections in either group.

- DMT:
• Post-transplantation infections: 15 upper respiratory tract infections (6 sinusitis, 2 bronchitis, 2 influenza, 1 streptococcal pharyngitis, 1 undefined pneumonia, 1 Mycoplasma pneumoniae, 1 tooth abscess, and 1 otitis media), 8 urinary tract infections, and 2 varicella-zoster reactivations.

Rate of infection per patient per year:
• HSCT: 0.19
• DMT: 0.23

Author’s conclusion
“In this preliminary study of patients with relapsing-remitting MS, nonmyeloablative HSCT, compared to DMT, results in prolonged time to disease progression. Further research is needed to replicate these findings and to assess long-term outcomes and safety.”

Main study findings
*Mancardi et al., 2015*¹⁷
Myeloablative AHSCT (n = 9) versus MTX (n = 12)

MRI outcomes for 17 patients (AHSCT [n = 8] versus MTX [n = 9]; lost 4 patients [1 in HSCT, 3 in MTX])
- New T2 lesions over 4 years:
  • AHSCT: Median = 2.5; mean = 2.75; range = 0 to 8
  • MTX: Median = 8; mean = 12.75; range = 2 to 34
  • Rate ratio (RR) (95% CI) = 0.21 (0.10 to 0.48); P = 0.00016
  • Worst case scenario: RR (95% CI) = 0.32 (0.16 to 0.66); P = 0.002
  • Best case scenario: RR (95% CI) = 0.19 (0.09 to 0.41); P < 0.0001
  • Adjusting for baseline Gd + lesions: RR (95% CI) = 0.19 (0.09 to 0.41); P < 0.0001
  • Using PP population: RR (95% CI) = 0.18 (0.06 to 0.52); P < 0.0001
  • Applying a mixed effects model with new T2 lesions on each MRI scan over time: RR (95% CI) = 0.28 (0.13 to 0.62); P = 0.002
  • Imputing the 4 missing patients as having 0 new T2 lesions: RR (95% CI) = 0.25 (0.05 to 0.74); P = 0.012
  • Imputing the 4 missing patients as having 35 new T2 lesions: RR (95% CI) = 0.34 (0.15 to 0.82); P = 0.016
  • Excluding 2 outliers in the MTX group: RR (95% CI) = 0.39 (0.22 to 0.69); P = 0.001

Gd + lesions during 4 years:
• AHSCT: 0
• MTX: 56% had at least 1 Gd + lesion; P = 0.029

Results did not change when adjusting for disease phase (relapsing-remitting versus progressive)

Clinical outcome, disability, and relapses for 20 out of 21 randomized patients (AHSCT [n = 9] versus MTX [n = 11])

ARR:
• AHSCT: 0.19
Progression at end of follow-up:

- AHSCT: 57%
- MTX = 48%; P = 0.50

EDSS change: No differences between groups at year 1, 2, 3 and 4

Safety (no statistical comparison)

- Mortality: None was found in both groups
- Early AEs:
  - AHSCT:
    - Grade 3: Febrile neutropenia, leukopenia, anemia, platelet count decrease, amenorrhea, leukopenia,
    - Grade 4: Leukopenia, anemia, platelet count decreased
  - MTX:
    - Grade 3: Neutrophil count decreased, amenorrhea, leukopenia, lymphocyte count decreased
    - Grade 4: Neutrophil count decreased
- Severe AEs:
  - AHSCT: Sepsis, late engraftment, prolonged hospitalization, systemic candidiasis, cytomegalovirus (CMV) reactivation, engraftment failure.
  - MTX: None

Author’s conclusion

“Intense immunosuppression followed by AHSCT is significantly superior to MTX in reducing MRI activity in severe cases of MS. These results strongly support further phase III studies with primary clinical endpoints.” (p. 981)

Main study findings

Alping et al., 2021

Myeloablative AHSCT (n = 139) versus ALZ (n = 132) versus matched patients treated with non-induction therapies (Natalizumab, dimethyl fumarate, rituximab, fingolimod; n = 2,486)

Safety

Mortality:
- AHSCT: 1 death (suicide); IR per 1,000 person-years (95% CI) = 1.7 (0.0 to 9.6)
- ALZ: 4 deaths (2 suicides, 1 heart attack, 1 CMV reactivation); IR per 1,000 person-years (95% CI) = 8.6 (2.3 to 22.0)
- Matched: 7 deaths; IR per 1,000 person-years (95% CI) = 0.7 (0.3 to 1.3)

Thyroid disease:
- AHSCT: 14; IR per 1,000 person-years (95% CI) = 34 (18 to 56)
- ALZ: 32; IR per 1,000 person-years (95% CI) = 109 (75 to 154)
- Matched: 45; IR per 1,000 person-years (95% CI) = 5.3 (3.9 to 7.1)

Non-thyroid autoimmune disease:
Any infection:

• AHSCT: 66; IR per 1,000 person-years (95% CI) = 275 (213 to 350)
• ALZ: 19; IR per 1,000 person-years (95% CI) = 56 (34 to 87)
• Matched: 405; IR per 1,000 person-years (95% CI) = 52 (47 to 58)

The incidence of infection was highest immediately after AHSCT but dropped to a level closer to alemtuzumab and matched control groups.

Infection diagnosed ≥ 6 months from therapy initiation:

• AHSCT: 35; IR per 1,000 person-years (95% CI) = 108 (75 to 150)
• ALZ: 15; IR per 1,000 person-years (95% CI) = 53 (30 to 87)
• Matched: 349; IR per 1,000 person-years (95% CI) = 51 (46 to 57)

Types of infections:

• AHSCT: Varicella zoster, herpes infections, bacterial sepsis
• ALZ: Varicella zoster, herpes infections, bacterial sepsis
• Systemic antibiotics were given to all patients after AHSCT and to a majority of patients after ALZ.

Author’s conclusion

“We confirmed a higher incidence of thyroid disease in alemtuzumab- and, to a smaller extent, AHSCT-treated patients and found a higher incidence of infection for AHSCT compared to both alemtuzumab and noninduction therapies. The incidence of non-thyroid autoimmune disease was low for both therapies.”18 (p. e1574)

Main study findings

Zhukovsky et al., 202119

Non-myeloablative AHSCT (n = 69) versus ALZ (n = 75)

Primary end point

• NEDA at 3 years:
  • AHSCT: 88% (95% CI, 80 to 97)
  • ALZ: 37% (95% CI, 26 to 52); P < 0.0001

• Freedom from MRI events:
  • AHSCT: 93% (95% CI, 86 to 99)
  • ALZ: 55% (95% CI, 44 to 69); P < 0.0001

• Freedom from clinical relapses:
  • AHSCT: 93% (95% CI, 86 to 100)
  • ALZ: 70% (95% CI, 59 to 83); P = 0.005

• Freedom from confirmed disability worsening (CDW):
  • AHSCT: 97% (95% CI, 93 to 100)
  • ALZ: 82% (95% CI, 73 to 92); P = 0.02
Secondary end points

• ARR:
  - AHSCT: 0.04
  - ALZ: 0.1; P = 0.03

• Proportions of patients who improved, stable or worsened:
  - AHSCT: 57%, 41%, 1%
  - ALZ: 45%, 43%, 12%; P = 0.06

• Median (IQR) EDSS change:
  - AHSCT:
    ▪ One year: -1 (-1.5 to 0)
    ▪ Two years: -1 (-2 to -0.5)
    ▪ Three years: -1 (-2.5 to -0.5)
  - ALZ:
    ▪ One year: 0 (-0.5 to 1.3); P < 0.0001
    ▪ Two years: 0 (-0.5 to 0.5); P < 0.0001
    ▪ Three years: 0 (-0.5 to 1); P < 0.0001

• Early AEs (during the first 100 days) grade ≥ 3:
  - AHSCT: 48 of 69 (70%); febrile neutropenia (58%), hypokalemia (19%)
  - ALZ: none

• Late AEs grade 3:
  - AHSCT: 1.4%; Lyme neuroborreliosis (n = 1)
  - ALZ: 6.7%; immune mediated thrombocytopenia (n = 4), breast cancer (n = 1)

• Autoimmune AEs:
  - AHSCT: 14 (20%); thyroid disease (n = 13; 19%)
  - ALZ: 35 (47%); thyroid disease (n = 31; 41%)

• Kaplan-Meier estimates of thyroid disease at 3 years (AHSCT: 21%; ALZ: 46%; P = 0.005)

• Late infection:
  - AHSCT: 4 herpes zoster (5.8%)
  - ALZ: 5 herpes zoster (6.7%)

• Mortality:
  - AHSCT: none
  - ALZ: none

Author’s conclusion

“In this observational cohort study, treatment with AHSCT was associated with a higher likelihood of maintaining ‘no evidence of disease activity’. Adverse events were more frequent with AHSCT in the first 100 days, but thereafter more common in patients treated with ALZ.”

Main study findings

Boffa et al., 2020

Myeloablative AHSCT (n = 25) versus ALZ (n = 32)
Primary end point

- NEDA at the end of observation:
  - AHSCT: 75%
  - ALZ: 56%
  - HR (95% CI) = 0.27 (0.08 to 0.84); P = 0.023
- Relapse-free survival:
  - AHSCT: 84%
  - ALZ: 69%
  - HR (95% CI) = 0.13 (0.02 to 0.63); P = 0.012
- MRI-activity-free survival:
  - AHSCT: 85%
  - ALZ: 59%
  - HR (95% CI) = 0.13 (0.03 to 0.59); P = 0.009
- CDW:
  - AHSCT: 88%
  - ALZ: 94%
  - HR (95% CI) = 0.25 (0.02 to 2.86); P = 0.263

Secondary outcomes

- ARR at 12 months:
  - AHSCT: 0.0
  - ALZ: 0.17; P = 0.03
- ARR at 24 months:
  - AHSCT: 0.1
  - ALZ: 0.09; NS
- ARR at 36 months:
  - AHSCT: 0.05
  - ALZ: 0.35; P = 0.02
- EDSS improvement: AHSCT promoted significant EDSS improvement compared with ALZ (P = 0.035)

Safety

- Serious infusion associated reactions:
  - AHSCT: 8
  - ALZ: 1
- Serious infectious AEs:
  - AHSCT: 24 (16 neutropenic fever, 8 sepsis)
  - ALZ: 3 (1 neutropenic fever, 2 pneumonia)
- CMC reactivation:
  - AHSCT: 2
  - ALZ: 0
- Herpes simplex virus 1:
• AHSCT: 1
• ALZ: 3

- Varicella-zoster virus:
  • AHSCT: 1
  • ALZ: 0
- Monoclonal gammopathy of undetermined significance:
  • AHSCT: 1
  • ALZ: 1
- Autoimmune disorders
  • AHSCT: 3 (1 thyroid disorder, 1 myositis, 1 asthma)
  • ALZ: 14 (9 thyroid disorders, 2 autoimmune thrombocytopenia, 2 psoriasis, 1 asthma)

**Author’s conclusion**

“Alemtuzumab and AHSCT are effective treatment choices for aggressive multiple sclerosis. AHSCT seems to be superior to alemtuzumab in inducing complete disease control and on promoting short-term disability improvement.”20 (p. 2047)

**Main study findings**

*Mariottini et al., 2019*21

Myeloablative AHSCT (n = 11) versus DMT (n = 41) in patients withdrew from natalizumab (NTZ) treatment

**Safety/AEs after AHSCT**

- Mortality or life-threatening complications, including PML: none
- Fever of unknown origin: 5
- Epstein-Barr virus reactivation: 5
- Gastrointestinal AEs: 4
- Pneumonia: 3
- Enteritis: 2
- Oral mucositis: 2
- CMV reactivation: 2
- Urinary infection: 1
- Varicella-zoster reactivation: 1
- Cutaneous erythema: 1
- Autoimmune thyroiditis: 1

NEDA at 3 years of follow-up:

- AHSCT: 54.5%
- DMT: 11.5%; P = 0.0212

ARR (clinical relapses):

- AHSCT: 0.0
- DMT: 0.67; P < 0.0001

Disability worsening:
• AHSCT:
  - Median (IQR) EDSS scores at baseline: 3.25 (2.0 to 4.5)
  - Median (IQR) EDSS scores at 3 years follow-up: 3.75 (2.0 to 4.5)
• DMT:
  - Median (IQR) EDSS scores at baseline: 2.0 (1.5 to 4.5)
  - Median (IQR) EDSS scores at 3 years follow-up: 4.25 (1.5 to 6.0)
• Confirmed improvement of EDSS scores:
  - AHSCT: 44.4%
  - DMT: 6.1%; P = 0.013
• Conversion to secondary-progressive MS:
  - AHSCT: 0
  - DMT: 4; P = 0.566

Author’s conclusion

“These data suggest that an aggressive therapy should be established after NTZ with the shortest possible washout period. AHSCT after 6 months from NTZ withdrawal appears to be safe.”

(p. 624)
## Table 6: Summary of Recommendations in Included Guidelines

<table>
<thead>
<tr>
<th>Recommendations and supporting evidence</th>
<th>Quality of evidence and strength of recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EBMT, Sharrack et al., 2020</strong>¹²</td>
<td></td>
</tr>
<tr>
<td><strong>Recommendations of AHSCT for MS:</strong></td>
<td></td>
</tr>
</tbody>
</table>
| • “AHSCT should be offered to patients with RRMS with high clinical and MRI inflammatory disease activity (at least 2 clinical relapses, or one clinical relapse with Gd-enhancing or new T2 MRI lesions at a separate time point, in the previous 12 months) despite the use of one or more lines of approved DMTs. Evidence best supports treatment in patients who are able to ambulate independently (EDSS 5.5 or less), who are younger than 45 years and have disease duration less than 10 years.”¹² (p. 289) | Level of evidence: I  
Strength of recommendation: S |
| • “Patients with ‘aggressive’ MS, who develop severe disability in the previous 12 months, are suitable candidates for AHSCT. Given the potential for irreversible disability, such patients may be considered even before failing a full course of DMT.”¹² (p. 289) | Level of evidence: II  
Strength of recommendation: CO |
| • “Patients with SPMS should be considered for AHSCT, preferably in a prospective clinical trial, only when inflammatory activity is still evident (clinical relapses and Gd-enhancing or new T2 MRI lesions) with documented disability progression in the previous 12 months.”¹² (p. 289) | Level of evidence: II  
Strength of recommendation: CO |
| • “Patients with PPMS should be considered for AHSCT, preferably in a prospective clinical trial, only when inflammatory activity is still evident (Gd-enhancing or new T2 MRI lesions) with documented disability progression in the previous 12 months.”¹² (p. 289) | Level of evidence: II  
Strength of recommendation: CO |
| • “Paediatric patients with MS who have breakthrough inflammatory disease with less toxic treatments may be considered for AHSCT.”¹² (p. 289) | Level of evidence: II  
Strength of recommendation: CO |
| **ASBMT, Cohen et al., 2019**²²       |                                                  |
| **Position Statement:**                |                                                  |
| “The ASBMT Task Force recommends revising the recommended indication for AHCT in MS to ‘standard of care, clinical evidence available’, for patients with relapsing forms of MS (RRMS or progressive MS with superimposed activity) who have prognostic factors that indicate a high risk of future disability, including ongoing clinical relapse or MRI lesion activity despite treatment with available DMTs, especially if disease activity continues despite treatment with high-efficacy DMTs and/or worsening disability.”²² (p. 851) | None |

AHCT = autologous hematopoietic cell transplantation; AHSCT = autologous hematopoietic stem cell transplantation; ASBMT = American Society for Bone Marrow Transplantation; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; Gd = gadolinium; MRI = MRI; MS = multiple sclerosis; PPMS = primary-progressive MS; RRMS = relapsing-remitting MS; SPMS = secondary-progressive MS.
Appendix 5: References of Potential Interest

Note that this appendix has not been copy-edited.

Previous CADTH Reports

Additional References

